2. Search Result
Search Result
Results for "

DRAK2

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-122629
    DRAK2-IN-1

    		DAPK Others
    DRAK2-IN-1, compound 16, is a potent, selective and ATP-competitive DRAK2 inhibitor with IC50and Kivalues of 3 nM and 0.26 nM, respectively. DRAK2-IN-1 also has inbitory effect on DRAK1 (IC50=51 nM) .
    DRAK2-IN-1
  • HY-152954
    DRAK1/2-IN-1

    		DAPK Inflammation/Immunology
    DRAK1/2-IN-1 (compound 10e) is an active dual DRAK1 and DRAK2 inhibitor with Kd values of 1 μM and 6 μM, respectively .
    DRAK1/2-IN-1
  • HY-178967
    DRAK1/2-IN-2

    		DAPK Apoptosis Interleukin Related Endogenous Metabolite Metabolic Disease
    DRAK1/2-IN-2 (Compound Y17) is a DRAK1/2 inhibitor with IC50 values for DRAK2 and DRAK1 of 353.2 nM and 507.4 nM respectively. DRAK1/2-IN-2 can enhance mitochondrial membrane potential and glucose-stimulated insulin secretion (GSIS). DRAK1/2-IN-2 resists lipotoxicity-induced cell apoptosis. DRAK1/2-IN-2 significantly inhibits the secretion of pro-inflammatory cytokine IL-1β, thereby exerting an anti-inflammatory effect. DRAK1/2-IN-2 can significantly lower the blood glucose levels of mice. DRAK1/2-IN-2 can be used in diabetes research.
    DRAK1/2-IN-2
  • HY-184326
    DRAK2-IN-2

    		DAPK Ser/Thr Protease ULK Mitochondrial Metabolism Apoptosis Metabolic Disease
    DRAK2-IN-2 is a selective DRAK2 inhibitor with an IC50 value of 198.5 nM. DRAK2-IN-2 inhibits DRAK2-mediated phosphorylation of ULK1 at the Ser56 site. DRAK2-IN-2 enhances insulin secretion, increases mitochondrial membrane potential, alleviates Palmitic acid (HY-N0830)-induced mitochondrial membrane potential damage and Apoptosis, and improves glucose tolerance in vivo. DRAK2-IN-2 can be used for the research of type 2 diabetes .
    DRAK2-IN-2
  • HY-RS13925
    STK17B Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    STK17B Human Pre-designed siRNA Set A contains three designed siRNAs for STK17B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    STK17B Human Pre-designed siRNA Set A
    STK17B Human Pre-designed siRNA Set A
  • HY-186224
    GW296115

    		PDGFR DAPK ULK p62 Autophagy Apoptosis Cancer
    GW296115 is a multi-target inhibitor with the following IC50 values against its targets: 8.4 nM for BRSK2, 21 nM for BRSK1, 1.8 μM for PDGFRβ, 5.5 nM for STK17B/DRAK2, 28 nM for DRAK1, 20 nM for PHKG1, and 89 nM for DCAMKL3. GW296115 downregulates the phosphorylation of S317 site on ULK1 and S351 site on P62, which are AMPK substrates driven by BRSK2. GW296115 does not alter the phosphorylation level of AMPK at T172, reduces nutrient deprivation-mediated Autophagy and autophagosome formation, and enhances Apoptosis. GW296115 exhibits anticancer activity against triple-negative breast cancer. GW296115 is applicable for breast cancer-related research [2].
    GW296115

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: